Document Type
Article
Publication Date
10-2024
Identifier
DOI: 10.1002/cpt.3405
Abstract
The Pharmacogene Variation Consortium (PharmVar) serves as a global repository providing star (*) allele nomenclature for the polymorphic human CYP4F2 gene. CYP4F2 genetic variation impacts the metabolism of vitamin K, which is associated with warfarin dose requirements, and the metabolism of drugs, such as imatinib or fingolimod, and certain endogenous compounds including vitamin E and eicosanoids. This GeneFocus provides a comprehensive overview and summary of CYP4F2 genetic variation including the characterization of 14 novel star alleles, CYP4F2*4 through *17. A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided.
Journal Title
Clinical pharmacology and therapeutics
Volume
116
Issue
4
First Page
963
Last Page
975
MeSH Keywords
Humans; Cytochrome P450 Family 4; Pharmacogenetics; Haplotypes; Alleles; Genetic Variation; Pharmacogenomic Variants
Keywords
Cytochrome P450 Family 4; Pharmacogenetics; Haplotypes; Alleles; Genetic Variation; Pharmacogenomic Variants
Recommended Citation
Zubiaur P, Rodríguez-Antona C, Boone EC, et al. PharmVar GeneFocus: CYP4F2. Clin Pharmacol Ther. 2024;116(4):963-975. doi:10.1002/cpt.3405
Comments
Grants and funding
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Publisher's Link: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3405